Teprotumumab for non-inflammatory thyroid eye dise IGF-1R expression

Eye

35, 2607-2612

DOI: 10.1038/s41433-020-01297-w

Citation Report

#	Article	IF	Citations
1	Orbital inflammatory disorders: new knowledge, future challenges. Current Opinion in Ophthalmology, 2021, 32, 255-261.	1.3	3
2	IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3125-e3142.	1.8	18
3	Teprotumumab for chronic thyroid eye disease. Orbit, 2022, 41, 539-546.	0.5	27
4	Teprotumumab for the treatment of chronic thyroid eye disease. Eye, 2022, 36, 1553-1559.	1.1	41
5	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment. Ophthalmology, 2022, 129, 438-449.	2.5	64
6	Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3809.	0.3	10
7	Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1219-1230.	0.9	10
8	Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects. Journal of Infusion Nursing, 2021, 44, 331-338.	1.2	2
9	The role of teprotumumab in chronic, clinically active thyroid eye disease. Eye, 2022, 36, 1500-1501.	1.1	2
10	Thyroid eye disease: From pathogenesis to targeted therapies. Taiwan Journal of Ophthalmology, 2022, 12, 3.	0.3	9
11	A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface. Journal of Neuro-Ophthalmology, 2022, 42, 26-34.	0.4	1
12	The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition. Ophthalmic Plastic and Reconstructive Surgery, 2023, 39, 4-12.	0.4	5
13	Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Gravesâ€™ Ophthalmopathy by Targeting Orbital Fibroblasts. Frontiers in Endocrinology, 2022, 13, .	1.5	3
14	Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States. Endocrine Practice, 2022, 28, 842-846.	1.1	10
15	Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. Indian Journal of Ophthalmology, 2022, 70, 2335.	0.5	6
16	Teprotumumab. Advances in Ophthalmology and Optometry, 2022, , .	0.3	0
17	Changing the face of thyroid eye disease. Eye, 2023, 37, 197-199.	1.1	1
18	Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S36-S46.	1.8	7

#	Article	IF	Citations
19	Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab. Ophthalmic Plastic and Reconstructive Surgery, 2023, 39, 150-155.	0.4	5
20	A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease. Thyroid, 2022, 32, 1547-1558.	2.4	5
21	Teprotumumab: A Review in Thyroid Eye Disease. Drugs, 2022, 82, 1663-1670.	4.9	4
22	Teprotumumab for the treatment of thyroid eye disease. Expert Opinion on Biological Therapy, 2023, 23, 123-131.	1.4	1
23	Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. Ophthalmic Plastic and Reconstructive Surgery, 2023, 39, 307-315.	0.4	1